Abera Bioscience Future Growth
Future criteria checks 0/6
Abera Bioscience's revenue is forecast to decline at 74.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | -74.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 30 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 4 | N/A | N/A | -19 | 1 |
| 12/31/2024 | 15 | N/A | N/A | -2 | 1 |
| 9/30/2024 | 13 | -4 | -9 | -8 | N/A |
| 6/30/2024 | 9 | -8 | -12 | -12 | N/A |
| 3/31/2024 | 5 | -13 | -15 | -15 | N/A |
| 12/31/2023 | 3 | -17 | -18 | -18 | N/A |
| 9/30/2023 | 0 | -19 | -18 | -18 | N/A |
| 6/30/2023 | 1 | -19 | -20 | -20 | N/A |
| 3/31/2023 | 1 | -20 | -20 | -20 | N/A |
| 12/31/2022 | 2 | -19 | -20 | -20 | N/A |
| 9/30/2022 | 2 | -17 | -16 | -16 | N/A |
| 6/30/2022 | 2 | -15 | -15 | -15 | N/A |
| 3/31/2022 | 1 | -11 | -9 | -9 | N/A |
| 12/31/2021 | 1 | -9 | -10 | -10 | N/A |
| 9/30/2021 | 1 | -8 | -10 | -10 | N/A |
| 6/30/2021 | 1 | -7 | -6 | -6 | N/A |
| 3/31/2021 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2020 | 1 | -4 | -3 | -3 | N/A |
| 11/30/2020 | 1 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 2 | -2 | -3 | -3 | N/A |
| 12/31/2018 | 2 | -3 | -2 | -2 | N/A |
| 12/31/2017 | 1 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 8WK's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 8WK's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 8WK's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 8WK's revenue is expected to decline over the next 3 years (-74.1% per year).
High Growth Revenue: 8WK's revenue is forecast to decline over the next 3 years (-74.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8WK's Return on Equity is forecast to be high in 3 years time